WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1998052966) TISSUE SPECIFIC PRODRUG
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1998/052966    International Application No.:    PCT/US1998/010285
Publication Date: 26.11.1998 International Filing Date: 19.05.1998
Chapter 2 Demand Filed:    17.12.1998    
IPC:
A61K 38/00 (2006.01), A61K 47/48 (2006.01), C07D 307/93 (2006.01), C07K 14/47 (2006.01)
Applicants: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDECINE [US/US]; 720 Rutland Avenue Baltimore, MD 21205 (US) (For All Designated States Except US).
ISSACS, John, T. [US/US]; (US) (For US Only).
DENMEADE, Samuel, R. [US/US]; (US) (For US Only).
CHRISTENSEN, S., Brogger [DK/DK]; (DK) (For US Only).
LILJA, Hans [SE/SE]; (SE) (For US Only)
Inventors: ISSACS, John, T.; (US).
DENMEADE, Samuel, R.; (US).
CHRISTENSEN, S., Brogger; (DK).
LILJA, Hans; (SE)
Agent: WETHERELL, John, R., Jr.; Fish & Richardson P.C. Suite 1400 4225 Executive Square La Jolla, CA 92037 (US)
Priority Data:
60/047,070 19.05.1997 US
60/080,046 30.03.1998 US
Title (EN) TISSUE SPECIFIC PRODRUG
(FR) BIOPRECURSEURS A SPECIFICITE TISSULAIRE
Abstract: front page image
(EN)The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific antigen (PSA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSA, the therapeutic drugs are activated and exert their toxicity. Novel sesquiterpene-$g(g)-lactones are also provided by the invention, and are designed to be linked to carrier moieties such as the peptides of the invention. Methods for treating cell proliferative disorders are also featured in the invention.
(FR)L'invention porte sur de nouveaux peptides bioprécurseurs contenant des sites de clivage où la coupure est spécifiquement produite par l'antigène spécifique de la prostate (PAS). Ces bioprécurseurs inhibent substantiellement la toxicité non spécifique d'une variété de produits thérapeutiques. Le PSA est sécrété par les cellules glandulaires de la prostate. Lors du clivage du bioprécurseur par le PSA, les produits thérapeutiques sont activés et exercent leur toxicité. L'invention porte également sur de nouveaux sesquiterpène-$g(g)-lactones conçus pour se fixer à des fragments porteurs tels que les peptides de l'invention. Elle porte en outre sur des procédés de traitement des troubles liés à la prolifération cellulaire.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)